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927and ventricular arrhythmia, conduction problems, tricuspid
regurgitation, and heart failure (8–11). Consequently, these
patients are monitored closely. Clinical follow-up typically
involves annual visits to the outpatient clinic with occasional
electrocardiography (ECG) and echocardiography, exercise
testing, 24-h ambulatory ECG, and cardiovascular magnetic
resonance imaging (CMR). The American College of
Cardiology/American Heart Association and European
Society of Cardiology guidelines recommend annual follow-
up (12,13).
However, there is considerable variation in the incidence
and onset of late sequelae. Whereas some patients experience
these complications early and often, others are able to live
relatively normal event-free lives. To date, it remains unclear
how to discriminate between high-risk and low-risk patients
and which diagnostic modalities are most informative in this
aspect. The aim of this study was to evaluate how to identify
patients at high risk for clinical events and to assess which
diagnostic modalities are best suited for this purpose.
Methods
Study design and groups. Between July 2006 and July 2009,
88 patients underwent multiple examinations in the setting
of the valsartan trial (14). This was a double-blind, random-
ized, placebo-controlled trial of the efﬁcacy of valsartan in
patients with a systemic right ventricle due to ccTGA or
atrially corrected TGA. Patients who were already using
angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers were instructed to discontinue these at
least 4 weeks before baseline examinations. All patients were
followed up from inclusion to August 2012, notwithstanding
the end of the trial. Approval by the local ethics committeewas
obtained, and all patients gave informed consent.
Event deﬁnitions. The primary endpoint was a composite
endpoint of clinical events. This included death; sustained
and nonsustained ventricular tachycardia; vascular events,
deﬁned as hemorrhagic or embolic cerebrovascular accidents,
transient ischemic attack, or myocardial infarction; tricuspid
regurgitation requiring invasive treatment; worsening heart
failure, deﬁned as an increase in nonstudy treatment
requirements, an increase in New York Heart Association
(NYHA) functional class, or hospital admission for wors-
ening symptoms of heart failure (15); and supraventricular
bradyarrhythmia or tachyarrhythmia requiring electrical
cardioversion, ablation, implantation of a pacemaker, or
a permanent change of antiarrhythmic medication. Patients
had to be free from supraventricular arrhythmia for at least
1 year since inclusion for an episode to be considered a new
event. Bafﬂe leakage or stenosis, failing conduits, or valvular
stenosis requiring percutaneous or surgical intervention were
additional endpoints but did not contribute to the composite
endpoint because they were not indicative of decline of the
systemic right ventricle (16).
Determinants of events. All participants underwent exten-
sive history taking, physical examination, regular and 24-hambulatory ECG, cardiopulmo-
nary exercise testing (CPET), ec-
hocardiography, and CMR or,
in case of contraindications for
CMR, multidetector-row compu-
ted tomography (MDCT).
HISTORY AND PHYSICAL EXAMINA-
TION. Extensive history taking,
review of available charts, and phy-
sical examination was performed
for each patient.
ELECTROCARDIOGRAPHY. Rhythm
(sinus or other), RR interval,
QRS duration, and corrected QT
interval were obtained manually
from standard (25 mm/s and
1 mV/cm) 12-lead ECGs.
24-H AMBULATORY ECG. A 24-h
ambulatory ECG was acquired
with a 3-channel Holter monitor
during normal out-of-hospital activities. Underlying rhythm
(sinus or other) and the number of premature ventricular
contractions, premature atrial contractions, couplets,
bigeminal cycles, and runs of nonsustained ventricular
tachycardia were recorded. Nonsustained ventricular tachy-
cardia was deﬁned as 3 consecutive ventricular premature
beats at >120 beats/min.
CARDIOPULMONARY EXERCISE TESTING. CPET was per-
formed on a bicycle ergometer. Work load was increased by
5 to 15 W until the patient reached maximum exercise
capacity. Continuous measurements of minute ventilation,
oxygen consumption (VO2), carbon dioxide production
(VCO2), heart rate, blood pressure, and ECG were per-
formed. Peak was deﬁned as the value at maximum load.
ECHOCARDIOGRAPHY. Parasternal and apical views were
obtained according to the recommendations of the Amer-
ican Society of Echocardiography (17). Tricuspid annular
plane systolic excursion was measured by M-mode. Right
ventricular volumes and function were assessed using
Simpson’s method in 4-chamber view. Ventricular volumes
were indexed using the Mosteller formula to calculate body
surface index (18). The degree of tricuspid regurgitation
(mild, moderate, severe) was estimated with color Doppler
by the width and length of the regurgitant jet and the
Doppler ﬂow pattern in the pulmonary veins (2,19).
CMR/MDCT. Detailed acquisition and analysis protocols are
described elsewhere (14). Contour tracing was performed by
a single observer using the method recommended by Winter
et al. (20). Stroke volume was deﬁned as end-diastolic volume
minus end-systolic volume, and ejection fraction was deﬁned
as stroke volume divided by end-diastolic volume. Ventricular
volumes and mass were indexed to body surface area.
Table 1 Baseline Characteristics
Characteristics
All
(N ¼ 88)
Event
(n ¼ 31)
No Event
(n ¼ 57) p Value
Age (yrs) 33  10 37  12 31  8 0.008
Male 57 (65) 18 (58) 39 (68) 0.331
Body mass index (kg/m2) 25  5 25  6 24  4 0.373
Body surface area (m2) 1.92  0.21 1.92  0.21 1.92  0.22 0.993
ccTGA 25 (28) 7 (23) 18 (32) 0.371
TGA 63 (72) 24 (77) 39 (68)
Mustard 48 (76) 21 (87) 27 (69) 0.098
Senning 15 (24) 3 (13) 12 (31)
Medication
Study medication (valsartan) 44 (50) 16 (52) 28 (49) 0.832
Previous angiotensin-converting
enzyme inhibitor/angiotensin II
receptor antagonist use
18 (21) 11 (36) 7 (12) 0.010
Beta-blockers 14 (16) 6 (19) 8 (14) 0.515
Diuretics 6 (7) 5 (16) 0 (0) 0.004
Antiarrhythmic drugs 10 (11) 7 (22) 3 (5) 0.014
NYHA functional class
I 60 (68) 15 (48) 45 (79) 0.003
II 20 (23) 9 (29) 11 (19) 0.298
III or IV 8 (9) 7 (23) 1 (2) 0.001
Pacemaker 23 (26) 12 (39) 11 (19) 0.048
ICD 1 (1) 0 (0) 1 (2) 1.000
MDCT 25 (28) 13 (42) 12 (21) 0.038
CMR 63 (72) 18 (58) 45 (79)
Values are mean  SD or n (%).
ccTGA ¼ congenitally corrected transposition of the great arteries; CMR ¼ cardiovascular magnetic resonance imaging; ICD ¼ implantable
cardioverter-deﬁbrillator; MDCT ¼ multirow detector computed tomography; NYHA ¼ New York Heart Association; TGA ¼ transposition of the great
arteries.
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version 20 (IBM, Armonk, New York) and R version 2.14.1
(The R Foundation for Statistical Computing, Vienna,
Austria). Data are summarized as number (%) for categorical
variables, mean  SD for continuous variables with normal
distribution, and median (interquartile range) for continuous
data with skewed distribution. Chi-square test or Student
independent t test were used to evaluate differences at
baseline between patients with and without clinical events
and to compare TGA-affected patients with ccTGA-
affected patients. Log-rank test was performed to assess
differences in the occurrence of clinical events. Missing data
were handled by multiple imputations using SPSS. The
relation between determinants and clinical events was
assessed using univariate and multivariate Cox proportional
hazards analysis. To identify determinants of clinical events,
exploratory univariate Cox regression was performed for all
relevant variables in the original dataset. Because peak heart
rate and systolic blood pressure (SBP) were possibly inﬂu-
enced by b-blockers or antiarrhythmic drugs, the hazard
ratio (HR) was adjusted for the use of these agents. We did
not aim to evaluate the efﬁcacy of pharmacological regimens,
so the use of medication was not entered in univariate or
multivariate analysis. When medication possibly inﬂuenced
the evaluated determinants, we did adjust for its use.
One parameter per diagnostic modality was entered in the
multivariate analysis. For each diagnostic modality, theparameter with the lowest Akaike information criterion in
univariate analysis was selected. Post-hoc exploratory mul-
tivariate analysis was performed to test whether the selected
parameters were indeed independent determinants and to
evaluate collinearity with other parameters from the same
modality.
The selected determinants were then entered in a stepwise
multivariate model using 5 imputed datasets. Parameters
were entered by decreasing availability and convenience in
a clinical setting. ECG and patient history were entered ﬁrst.
Subsequently, determinants obtained by diagnostic modali-
ties requiring increasing expertise (laboratory results, CPET,
24-h ambulatory ECG, echocardiography, and ﬁnally CMR
or MDCT) were added in turn to assess the additional value
of these modalities. Each subsequent model was built with
the signiﬁcant independent predictors from the previous
model and the selected parameter from the diagnostic
modality that was next in the hierarchy of expertise. Receiver
operating curves for censored data (R package survival ROC)
were used to visualize the value of the multivariate model at
each step. For continuous determinants, relevant cutoffs were
obtained using individual receiver-operating characteristic
curves. Using the original dataset, Kaplan-Meier curves were
plotted for determinants that independently identiﬁed
patients at risk for clinical events. To evaluate if the most
valuable determinants were applicable in both TGA and
ccTGA, univariate analysis for each group and interaction
Table 2 Distribution of Events
Events All Included in Composite*
Death
Cardiac 3 1
Noncardiac 1 0
Ventricular tachycardia
Sustained 0 0
Nonsustained 4 2
Vascular events
Transient ischemic attack 1 1
Myocardial infarction 1 0
Tricuspid regurgitation
Repair 1 0
Replacement 1 0
Worsening heart failure
De novo 11 9
Recurrent 4 3
Supraventricular arrhythmia
De novo 12 10
Recurrent 7 5
Total 46 31
*In case of multiple events, the ﬁrst event was included in the composite endpoint.
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929analysis were performed. For all analyses, a 2-tailed p value
of <0.05 was used as the criterion for statistical signiﬁcance.
Results
A total of 88 patients with a systemic right ventricle were
included. The mean age of the patients was 33  10 years,
57 (65%) were male, and 25 (28%) had ccTGA. Twenty-ﬁve
participants (28%) underwent MDCT because of contrain-
dications for CMR (24 with a pacemaker and 1 with a metalFigure 1 Event-Free Survival
The composite endpoint is represented by the green curve.intraocular foreign body). During a cumulative follow-up of
379 years (median of 4.3 years) 31 patients (35%) experi-
enced 46 clinical events for an annual risk of 12%. Patients
who experienced events were older, were in a worse NYHA
functional class, were more likely to use diuretics and anti-
arrhythmic drugs, more often had a pacemaker, and more
often used renin-angiotensin-aldosterone system inhibitors
at baseline screening. There was no difference in the allo-
cation of study medication between patients with and
without events (Table 1). One patient with TGA had an
implantable cardioverter-deﬁbrillator.
Events. Four patients died (3 of end-stage right ventricle
failure and 1 of end-stage pulmonary disease). An overview
of all clinical events and which comprised the composite
endpoint is presented in Table 2. Cumulative event-free
survival at 4-year follow-up was 63% (Fig. 1).
Bafﬂe problems occurred in 2 patients during follow-up,
for which 1 patient underwent cardiac surgery to relieve
symptomatic bafﬂe leakage and 1 patient underwent intra-
bafﬂe stenting for symptomatic bafﬂe stenosis. In both
patients, turbulent ﬂow was already visible on baseline
echocardiography. One patient with ccTGA and pulmonary
atresia underwent dilation of a pulmonary homograft
stenosis.
Determinants of clinical events. Table 3 lists the results of
the univariate analysis. History, ECG, laboratory testing,
CPET, 24-h ECG, echocardiography, and CMR/MDCT all
yielded prognostic information. The most valuable indepen-
dent determinants of clinical events for each diagnostic
modality were symptoms (NYHA functional class II) (HR:
2.45; p ¼ 0.01), the absence of sinus rhythm (HR: 2.16;
p ¼ 0.04), N-terminal pro-hormone of brain natriuretic
peptide (HR: 1.5; p¼ 0.06), peak SBP (HR: 0.78; p< 0.01),
number of premature ventricular complexes in 24 h (HR: 1.28;
p < 0.01), right ventricular end-diastolic volume index
(RVEDVi) measured by echocardiography (HR: 1.41;
p < 0.01), and CMR/MDCT (HR: 1.21; p < 0.01).
Sex, type of transposition (ccTGA vs. surgically corrected
TGA), a history of supraventricular tachycardia, non-
sustained ventricular tachycardia on 24-h ECG, tricuspid
regurgitation, tricuspid annular plane systolic excursion, and
right ventricular ejection fraction measured by echocardiog-
raphy were not signiﬁcantly associated with clinical events.
Using only readily available history and ECG, the strongest
determinants of clinical events were symptoms (NYHA
functional class II) (HR: 2.42; p ¼ 0.02) and the absence
of sinus rhythm on baseline ECG (HR: 2.16; p ¼ 0.04).
On receiver-operating characteristic analysis, the area under
the curve was 0.66 (Fig. 2). Adding laboratory results
(N-terminal pro-hormone of brain natriuretic peptide) did
not provide additional prognostic information. Peak exercise
SBP was the strongest determinant derived from CPET
(HR: 0.82; p < 0.01) and improved the model considerably
(area under the curve of 0.77). Twenty-four–hour ambulatory
ECG did not provide additional information. RVEDVi
measured by echocardiography (HR: 1.16; p ¼ 0.05)
Table 3 Univariate Cox Proportional Hazards Analysis
Variables
Total
(N ¼ 88)
Event
(n ¼ 31)
No Event
(n ¼ 57)
Univariate Analysis
HR p Value*
History
Age (yrs) 33  10 37  12 31  8 1.33y 0.064
Male 57 (65) 18 (58) 30 (68) 0.72 0.375
TGA (vs. ccTGA) 63 (72) 24 (77) 39 (68) 1.75 0.194
Complex (vs. isolated) 30 (34) 9 (29) 21 (37) 0.69 0.347
Symptomatic (NYHA functional class II) 28 (32) 16 (52) 12 (21) 2.45 0.014
Episode(s) of atrial ﬁbrillation 26 (30) 13 (42) 13 (23) 1.66 0.165
Episode(s) of heart failure 7 (8) 5 (16) 2 (4) 2.73 0.042
Complete heart block 7 (8) 4 (13) 3 (5) 2.98 0.095
Sinus dysfunction 21 (24) 8 (26) 13 (23) 0.60 0.505
ECG
Absence of sinus rhythm 21 (24) 12 (39) 9 (16) 2.16 0.043
QTc (ms) 432  39 445  43 425  36 1.07y 0.068
QRS width (ms) 119  30 128  32 114  28 1.18y 0.083
Laboratory tests
Hemoglobin (mmol/l) 9.3  0.9 9.1  0.8 9.5  0.9 0.13 0.724
Glomerular ﬁltration rate (ml/min) 124  30 118  26 126  32 0.99 0.382
Aspartate aminotransferase (U/l) 26  9 25  10 27  9 0.98 0.434
Alanaine aminotransferase (U/l) 29  14 26  11 30  15 0.97 0.150
g-Glutamyltransferase (U/l) 37 (25–78) 31 (24–84) 38 (28–62) 1.00 0.242
NT-proBNP (ng/l) 210 (126–478) 328 (210–791) 159 (101–342) 1.50z 0.056
Cardiopulmonary exercise testing
Peak load (W) 169  58 136  54 186  54 0.86y 0.001
Peak heart rate (beats/min) 159  27 148  30 164  23 0.89yx 0.085
Peak systolic blood pressure (mm Hg) 177  28 164  18 184  30 0.78yx 0.002
Peak V0O2 (ml/min/kg) 27  7 24  8 29  7 0.53y 0.016
Holter monitoring
Absence of sinus rhythm 16 (19) 10 (35) 6 (11) 2.00 0.109
Presence of nonsustained ventricular tachycardia 14 (17) 7 (27) 7 (13) 1.60 0.312
Presence of PVC couplets 27 (34) 8 (32) 19 (35) 0.53 0.171
Presence of bigeminal cycles 24 (29) 13 (48) 11 (20) 2.30 0.036
Number of PVC/24 h 90 (9–378) 248 (71–1,160) 28 (7–218) 1.28z 0.008
Presence of PAC runs 26 (32) 5 (19) 21 (39) 0.45 0.105
Presence of PAC couplets 30 (37) 8 (31) 22 (40) 0.67 0.347
Echocardiography
Tricuspid annular plane systolic excursion (cm) 1.4  0.4 1.3  0.4 1.4  0.4 0.57 0.300
Tricuspid regurgitation 37 (45) 15 (50) 22 (42) 2.18 0.164
Left ventricular outﬂow tract obstruction 20 (23) 6 (19) 14 (25) 1.08 0.890
RVEDVi (ml/m2) 58  21 70  26 53  17 1.41y 0.001
RVESVi (ml/m2) 37  16 46  21 32  11 1.50y 0.001
RVEF (%) 36  10 34  9 37  10 0.96 0.196
CMR/MDCT
RVEF (%) 36  7 33  9 38  7 0.95 0.022
RVEDVi (ml/m2) 133  35 155  40 120  25 1.21y 0.000
RVESVi (ml/m2) 86  31 105  37 75  20 1.20y 0.000
Right ventricular mass index (g/m2) 40  11 46  12 37  9 1.66y 0.001
Left ventricular ejection fraction (%) 53  10 49  11 55  9 0.97 0.041
Left ventricular end-diastolic volume index (ml/m2) 84  23 95  27 77  17 1.16y 0.005
Left ventricular end-systolic volume index (ml/m2) 40  18 49  23 34  12 1.19y 0.009
Left ventricular mass index (g/m2) 35  11 38  12 33  9 1.18y 0.237
Values are mean  SD, n (%), and median (interquartile range). *p value for HR. yHR per 10 U. zHR of log-transformed variable. xAdjusted for use of b-blocker and antiarrhythmic medication.
ECG ¼ electrocardiography; HR ¼ hazard ratio; NT-proBNP ¼ N-terminal pro-hormone of brain natriuretic peptide; PAC ¼ premature atrial complex; PVC ¼ premature ventricular complex; RVEDVi ¼ right
ventricular end-diastolic volume index; RVEF ¼ right ventricular ejection fraction; RVESVi ¼ right ventricular end-systolic volume index; other abbreviations as in Table 1.
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Figure 2 Receiver-Operating Characteristic Curves at 4 Years
Time-dependent receiver-operating characteristic curves at 4 years for the best predictors of each diagnostic modality (Table 3). The combination of CMR and CPET is most
valuable for predicting events. CMR ¼ cardiovascular magnetic resonance imaging; CPET ¼ cardiopulmonary exercise testing; ECG ¼ electrocardiography; MDCT ¼ multirow
detector computed tomography.
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931improved the model (area under the curve of 0.81).
However, measuring RVEDVi with CMR or MDCT
(HR: 1.20; p < 0.01) was superior (area under the curve of
0.88). The ﬁnal model included peak exercise SBP,
RVEDVi measured by magnetic resonance imaging, and
RVEDVi measured by echocardiography (Table 4). The
latter was no longer a signiﬁcant independent predictor.
Kaplan-Meier curves of all determinants that were entered
in the multivariate analysis are presented in Figure 3. For peak
exercise SBP, RVEDVi measured by echocardiography, and
RVEDVi measured by CMR orMDCT, cutoff values of 180
mmHg, 50 ml/m2, and 150 ml/m2, respectively, were chosen
by individual receiver-operating characteristic analysis.
Patients (n ¼ 26) with RVEDVi <150 ml/m2 and peak
exercise SBP>180 mmHg had an annual event rate of 0.9%.
The probability of event-free survival was signiﬁcantly better
compared with patients who had RVEDVi >150 ml/m2,
peak exercise SBP <180 mm Hg, or both (Fig. 4). Using the
combination of these 2 determinants, a sensitivity of 96% andnegative predictive value of 96% was obtained. Conversely,
the annual event rate of patients with RVEDVi >150 ml/m2
and peak exercise SBP <180 mm Hg was 19%. This corre-
sponded to a speciﬁcity of 94% and a positive predictive value
of 81% (Fig. 5).
TGA versus ccTGA. Table 5 compares patients with
TGA and patients with ccTGA regarding some of the
baseline characteristics, determinants, and events. Patients
with ccTGA were older and experienced fewer episodes of
supraventricular arrhythmia. Sinus node dysfunction was
more prevalent in the TGA group, whereas complete heart
block occurred more in patients with ccTGA.
Both determinants in the ﬁnal model were equally appli-
cably to patients with TGA and patients with ccTGA. HRs
for RVEDVI were 1.3 (p ¼ 0.009) in the ccTGA group and
1.2 (p¼ 0.001) in theTGAgroup and for peak SBPwere 0.72
(p ¼ 0.028) and 0.80 (p ¼ 0.031), respectively. Moreover,
there was no signiﬁcant interaction effect for ccTGA versus
TGA (p interaction RVEDVI ¼ 0.902, peak SBP ¼ 0.542).
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This study demonstrates a high annual risk of clinical events
in patients with a systemic right ventricle. Exercise testing
and CMR or MDCT were most useful to identify patients
at risk for clinical events. Patients with a peak exercise SBP
below 180 mm Hg and an RVEDVi above 150 ml/m2 had
a 20-fold higher annual event rate than patients without
these risk factors.
Interpretation. In patients with a systemic right ventricle,
further right ventricular deterioration is often accompanied
by late sequelae such as arrhythmia or symptomatic heart
failure. This study found RVEDVi and peak SBP to be
strong determinants of these late clinical events.
Although TGA and ccTGA differ in geometry and ﬁber
orientation, they share many characteristics and both face
high systemic pressures, which will eventually lead to decline
of the cardiac pump and accompanying events. The TGA
and ccTGA groups differed by age and the prevalence of
different arrhythmias. However, the most valuable deter-
minants of clinical events were remarkably similar in both
groups. This study did not include single systemic right
ventricles. Consequently, it remains unclear if similar pa-
rameters determine prognosis in these patients.
Ejection fraction does not adequately reﬂect the condition
of the systemic right ventricle, because tricuspid regurgita-
tion, which is common in these patients and an additional
burden on the right ventricle, paradoxically increases ejection
fraction. The systemic right ventricle compensates for the
systemic afterload with right ventricular enlargement and
hypertrophy (21). Ventricular enlargement may lead to
tricuspid regurgitation, which leads to volume overload and
even more dilation (22). Consequently, right ventricular
end-diastolic volume might better reﬂect the status of the
systemic right ventricle. This is supported by studies in the
setting of pulmonary arterial hypertension, also a pressure-
overloaded right ventricle. In these patients, right ventric-
ular end-diastolic volume has been shown to predict
outcome better than ejection fraction as well (23).
The right ventricular end-systolic volume index (RVEDVi)
was almost as strong a determinant as right ventricular end-
diastolic volume. Right ventricular end-diastolic volume not
only reﬂects the dilation of the right ventricle but also the
volume that the ventricle can no longer eject. Therefore, it
reﬂects right ventricular function as well. Theoretically, this
parameter could be superior to RVEDVi and is equally
unbiased by tricuspid regurgitation. However, measuring the
right ventricular end-systolic volume is complicated, because
it is difﬁcult to discern impacted trabeculae frommyocardium.
Consequently, the larger measurement error might be
responsible for this parameter not making the ﬁnal model.
Furthermore, there were large discrepancies between ven-
tricular volumes measured by echocardiography and CMR/
MDCT. Consequently, different criteria should be applied
when identifying patients at risk for late sequelae. Whereas
an RVEDVi above 50 ml/m2 measured by echocardiography
Figure 3 Kaplan-Meier Analyses
Kaplan-Meier curves for symptoms, sinus rhythm, RVEDVi (echo), peak exercise SBP, and right ventricular end-diastolic volume index measured by CMR or MDCT). RVEDVi ¼
right ventricular end-diastolic volume index; RVEDVi (echo) ¼ right ventricular end-diastolic volume index measured by echocardiography; SBP ¼ systolic blood pressure; other
abbreviations as in Figure 2.
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measured by CMR or MDCT was 150 ml/m2.
The ﬁnding that lower peak SBP provides prognostic
information in patients with and without heart failure, either
alone or adding to existing predictors, is not a new concept
(24–27). Peak SBP has been repeatedly found to be an
independent predictor of cardiac events and/or death in
patients with heart failure (24,28–31) or post–myocardial
infarction (25,26). Moreover, it occasionally outperforms
conventional predictors, such as peak VO2 (24,28,29).
Cardiac response to stress has been shown to be abnormal
in patients with a systemic right ventricle (32–36) and
prognostic of mortality and clinical events (37,38). Further-
more, during a 4-year follow-up study in patients with
systemic right ventricles (atrially corrected TGA), peak SBP
was clearly diminished in patients who experienced cardiac-
related emergencies compared with patients without events(38). Although it was not the focus of the study, baseline
differences in peak SBP were statistically of the same order as
peak VO2 and VE/VO2 slope, the most valuable predictors
according to the multivariate model of the study.
Peak SBP and peak VO2 both reﬂect the performance of
the cardiac pump, which generates both ﬂow (cardiac
output) and pressure. Whereas, according to Fick’s principle,
peak VO2 can be seen as a measure of ﬂow, peak SBP is
a measure of the pressure-generating capacity (29,39,40).
Because the right ventricle is essentially “built” for a high-
volume but low-pressure environment, failing to generate
adequate pressure (low peak SBP) may be the ﬁrst sign of
imbalance of the compensatory mechanisms of the systemic
right ventricle. Accordingly, peak SBP might outperform
peak VO2 as a determinant of events in these patients.
As can be expected, cutoff values for peak SBP differ be-
tween groups and endpoints. They ranged from 120 mm Hg
Figure 4 Prediction Model
Cox proportional hazards model including RVEDVi and peak exercise SBP.
Abbreviations as in Figure 3.
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patients with more general heart failure (24,30). In this view,
the cutoff value of 180 mm Hg in our cohort was rather
high. However, patients with a systemic right ventricle are
generally much younger than patients with acquired heart
failure and many remain asymptomatic, which may explain
why they perform generally well on exercise testing.Figure 5 Scatterplot
Patients with and without events by RVEDVi and peak exercise SBP. NPV ¼ negative preThere was no difference in valsartan treatment allocation
between patients with and without events. Even though val-
sartan has been shown to reduce mortality and morbidity in
patients with acquired heart disease (41), our study was not
powered to detect a treatment effect on clinical endpoints (42).
Clinical implications. Patients with a dilated right ventricle
and patients with an inadequate blood pressure response to
exercise are at increased risk for clinical events. Preventing
a decline in exercise capacity and progression of right ventric-
ular dilation might also prevent future events. In patients with
a systemic right ventricle, exercise training has been shown to
increase VO2peak (43). Moreover, Belardinelli et al. (44,45)
showed that, in addition to improved VO2peak, exercise
training also reduced clinical events in patients with acquired
left ventricular heart failure. Furthermore, in a recent trial by our
group, inhibition of the renin-angiotensin-aldosterone system
attenuated systemic right ventricular dilation, although the
effect was small (42). Finally, patients without these risk factors
have a very low risk of complications and might be considered
for biannual instead of annual follow-up.
Study limitations. A control cohort to test the consistency
of the associations found in this study was not available,
which could raise concerns about generalizability. In addi-
tion, our primary endpoint was heterogeneous, although
composite endpoints combining arrhythmia, heart failure,
and other cardiac complications have previously been used in
this population (38). However, most late sequelae in these
patients stem from underlying right ventricular deteriora-
tion. In this light, bafﬂe leakage and stenosis were not
considered an event, because these were unlikely to be
caused by deterioration of the right ventricle.
Furthermore, the temporal resolution of MDCT is
lower than that of CMR. As a result, MDCT tends todictive value; PPV ¼ positive predictive value; other abbreviations as in Figure 3.
Table 5 Patients With TGA Versus Patients With ccTGA
Characteristics TGA (n ¼ 63) ccTGA (n ¼ 25) p Value
Age (yrs) 30  6 40  13 0.001
Ventricular septal defect 9 (13) 7 (28) 0.133
Atrial septal defect 1 (2) 1 (4) 0.490
Pulmonary stenosis 11 (18) 9 (36) 0.061
Aortic coarctation 2 (3) 0 (0) 1.000
History of supraventricular tachycardia 19 (30) 7 (28) 0.841
Sinus dysfunction 20 (32) 1 (4) 0.006
Complete heart block 2 (3) 5 (21) 0.009
Pacemaker 17 (27) 6 (24) 0.774
ICD 1 (2) 0 (0) 1.000
Predictors
Symptomatic (NYHA functional class II) 20 (32) 8 (32) 0.982
Absence of sinus rhythm 12 (19) 9 (36) 0.092
NT-proBNP (ng/l)* 209 (131–356) 273 (80–784) 0.182
Peak systolic blood pressure (mm Hg) 177  27 176  30 0.962
Number of PVC/24 h* 52 (7–261) 206 (28–1,239) 0.118
RVEDVi echocardiography (ml/m2) 61  21 51  21 0.146
RVEDVi CMR/MDCT (ml/m2) 133  35 134  37 0.865
Events
Death 2 (3) 2 (8) 0.327
Ventricular tachycardia 2 (3) 2 (8) 0.327
Vascular event 1 (2) 1 (4) 0.490
Tricuspid regurgitation 2 (3) 0 (0) 0.510
Worsening heart failure 10 (16) 5 (20) 0.642
Supraventricular arrhythmia 17 (27) 2 (8) 0.051
Composite 24 (38) 7 (28) 0.371
Values are mean  SD, n (%), and median (interquartile range). *p value for log-transformed variable.
Abbreviations as in Tables 1 and 3.
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systolic volume). Because patients who underwent MDCT
had more events, this might lead to an underestimation of
the predictive value of RVEDVi. Finally, because data on
coronary artery anatomy were only sporadically available, we
were unable to evaluate the predictive value of this
parameter.Conclusions
Patients with a systemic right ventricle have a high annual
risk of clinical events. The combination of exercise testing
and CMR was most valuable when determining the risk of
clinical events. Patients with a peak exercise SBP below 180
mm Hg during exercise and an RVEDVi above 150 ml/m2
had a 20-fold higher annual event rate than patients without
these risk factors. In addition to echocardiography and
ECG, regular CMR and exercise testing are important for
risk assessment in these patients.
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